Loyal

Loyal (operating at loyal.com) is a clinical-stage veterinary medicine company pioneering pharmaceutical interventions to extend the lifespan and healthspan of dogs. Founded by Blake Scholl, the company is headquartered in San Francisco, CA, and represents a bold departure from traditional pet care by focusing on longevity science rather than symptom management. At its core, Loyal is developing LOY-002, a prescription daily pill designed to target cellular mechanisms of aging in senior dogs, aiming to maintain vitality and delay age-related decline. This approach leverages cutting-edge biotechnology to address a critical gap in veterinary medicine, where interventions for canine aging have historically been limited to palliative care. Veterinarians and pet owners benefit from a scientifically grounded solution that could redefine geriatric care for dogs, potentially extending their healthy years by years. Backed by a $150 million funding round across six rounds, Loyal has attracted prominent investors including age1, Baillie Gifford, Collaborative Fund, and Concord Health Partners, underscoring its potential to disrupt the $100+ billion global pet care market through innovation.